Please login to the form below

Not currently logged in
Email:
Password:

Janssen’s UK head moves to China

Cesar Rodriguez appointed managing director of Xian Janssen
Janssen Cesar Rodriguez.

Janssen's managing director for the UK and Ireland has moved to a new role in China.

Cesar Rodriguez has been named managing director and president of Xian Janssen, the Chinese subsidiary of Johnson & Johnson's pharma division Janssen.

The move marks another step in a well-travelled career for Rodriguez, which includes spells in Spain, Romania and, during the Arab Spring, Egypt.

At his most recent role in the UK, Rodriguez's significant accomplishments included leading Janssen as the top-ranked pharma company in The Sunday Times' Best Companies To Work For in 2012 and achieving a 100 per cent success rate with NICE in 2013.

The company also won The Accenture Award for PMEA Company of the Year at PMEA 2013 last week.

Kim Taylor, company group chairman, Janssen Pharmaceuticals, Asia Pacific, praised the experience of Rodriguez.

She said: “With almost two decades of work experience at Janssen in various commercial and senior leadership roles, Cesar will bring to the company in-depth understanding and insights on business strategy, a track record of delivering business growth in highly complex and diverse markets, and a career-long commitment to integrity and talent development.”

Rodriguez said he was looking forward to the challenges offered by a new market.

He said: “China faces tremendous unmet medical need, and I am excited to be joining Xian Janssen at a time when we are in an unparalleled position to serve that need and to bring important life-saving drugs to patients and families who need them.”

5th December 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
...
Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...

Infographics